Large Reduction in Adiponectin During Pregnancy Is Associated With Large-for-Gestational-Age Newborns

Tove Lekva1, Marie Cecilie Paasche Roland2,3, Annika E Michelsen1,4

  • 1Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, 0027 Oslo, Norway.

Insights

Maternal adiponectin levels during pregnancy are linked to fetal growth. Lower adiponectin and its decrease over pregnancy predict larger birth weight and large-for-gestational age infants.

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Perinatal medicine

Background:

  • Intrauterine exposure to maternal obesity increases offspring risks for obesity and chronic diseases.
  • Factors influencing the intrauterine environment and their impact on fetal growth are not fully understood.

Purpose of the Study:

  • To examine the association between maternal adiponectin and leptin levels during pregnancy and infant birth weight.
  • To investigate the relationship between placental gene expression and birth weight.

Main Methods:

  • Prospective cohort study of 300 pregnant women.
  • Repeated measurements of adiponectin, leptin, and oral glucose tolerance tests.
  • Analysis of placental mRNA expression for adiponectin receptors and nutrient transporters.

Main Results:

  • Lower circulating adiponectin levels were observed in mothers of large-for-gestational age (LGA) infants.
  • A significant decrease in adiponectin from early to late pregnancy independently predicted birth weight.
  • Placental expression of adiponectin receptor 2 and amino acid transporter A was negatively correlated with birth weight.

Conclusions:

  • Maternal adiponectin is a significant predictor of fetal growth and birth weight.
  • Adiponectin's role in fetal growth is independent of maternal body mass index and insulin resistance.
Abstract

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
316